In June this year the new Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) started its normal working activities. Located at the highest point of the campus, the CMCiB is a centre promoted by the Germans Trias i Pujol Research Institute (IGTP) and dedicated to biomedical research and training. The centre is an important addition to scientific infrastructures in southern Europe and is the only one in Spain, it has been set up to become a reference in comparative medicine, bioimaging and computational models with a clear remit to promote alternative research models and methods
At the IGTP TODAY
The IGTP-PMPPC applied health technology spin-off is one of five selected by ACCIÓ in the first edition of 'Road to Boston'. Aniling is one of five applied health technology Catalan start-ups that has started an intensive six-month tailored program to prepare for entry to Boston, one of the principal hubs in this field, to establish first contacts with key players in the sector.
The Germans Trias Hospital and the IGTP in tandem have joined with the ten Catalan hospitals and their associated research centre who have agreed to participate in the Center for the Integration of Medicine and Innovative Technologies in Catalonia (CIMTI)
MIT to Advise on an IGTP Project to Develop a Gel for Lesions Sustained during Digestive Endoscopies
In a program run by the Spanish Foundation for Innovation and Future Health (FIPSE) the Massachusetts Institute of Technology (MIT) has selected an IGTP project for its Mentoring Program in Biomedicine. The project is to develop a family of hydrogels to answer unmet needs in digestive endoscopies and avoid complications in endoscopic procedures
Researchers at Can Ruti Campus enter into a licence agreement for the worldwide rights to the use of biomarker soluble neprilysin (sNEP) for assessing risk stratification and prognosis of heart failure patients
23 April 2016. The group led by Dr Antoni Bayés-Genís of the Department of Cardiology of the Germans Trias i Pujol Hospital (HUGTiP) and the Germans Trias i Pujol Health Research Institute (IGTP) have signed a licence agreement with the American Company Critical Diagnostics for biomarker soluble neprilysin (sNEP).